Author/Authors :
Veisani Yousef نويسنده Department of Clinical Epidemiology, Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran Veisani Yousef , Delpisheh Ali نويسنده Department of Clinical Epidemiology, Ilam University of Medical Sciences, Ilam, Iran Delpisheh Ali
Abstract :
Context Resent reviews have shown that about 18% of all child
cancers are leukemia. Track of the survival rate can help researchers
improve quality of life of patients through improving screening or
discovery of better treatments. Objectives This review aimed at
estimating the 5-year survival rates and associated factors of childhood
leukemia in Iran. Data Sources We carried out a systematic review
through search of relevant studies published in English (PubMed, Scopus,
Google scholar, and ISI) and Persian databases (Magiran, Medlib, SID,
and Iran Medex). Study Selection The study included all epidemiologic
studies that estimated survival rate in children with leukemia in Iran
during years 2002 to 2015, and a standardized manner was used for
extraction of information. Data Extraction The entire text or summary of
all searched articles was extracted and then, related articles were
selected, and irrelevant ones were excluded. Fixed and random effects
models were calculated by the STATA using standard meta-analysis
methods. Heterogeneity was assessed by I² statistics. Results The
overall 5-year survival rate in patients with childhood leukemia in Iran
was 0.65 (95% CI, 0.62 to 0.67, 10 studies), in the acute lymphoblastic
leukemia (ALL) subtype was 71.0% (95% CI: 68.0 to 74.0), and in the
acute myeloid leukemia (AML) subtype was 46.0%. Results of the meta
analysis showed significant poor survival with relapse (heart rate (HR)
1.59, 95% confidence interval (CI) 1.27 to 1.98) and white blood count
(WBC) counts ≥ 50,000 (HR 2.92, 95% CI 1.23 to 4.60). Conclusions The
results showed that 5-year survival rates in patients with AML were
lower than patients with ALL. The results of this meta analysis strongly
support the need for future research, action, and guidance for
clinicians to improve health-related quality of life and outcomes for
children with leukemia.